Interferon Alfa-2b, Recombinant
Tyrosine Kinase Inhibitor
DB00105
Approved Indication
For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.
2
Targets
0
Resistance Mutations
1
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which upon dimerization activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.
Details
DrugBank ID
DB00105 ↗
Approval Date
1986-06-04
Molecular Weight
— g/mol
Drug Class
Tyrosine Kinase Inhibitor
ATC Codes
L03AB05
Synonyms
Interferon alfa-2b, Interferon α-2b, Intron (Interferon α2b)
Drug References (DrugBank)